BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 7797130)

  • 1. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography.
    Friess H; Langhans J; Ebert M; Beger HG; Stollfuss J; Reske SN; Büchler MW
    Gut; 1995 May; 36(5):771-7. PubMed ID: 7797130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
    Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
    Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.
    Imdahl A; Nitzsche E; Krautmann F; Högerle S; Boos S; Einert A; Sontheimer J; Farthmann EH
    Br J Surg; 1999 Feb; 86(2):194-9. PubMed ID: 10100786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases.
    Zimny M; Bares R; Fass J; Adam G; Cremerius U; Dohmen B; Klever P; Sabri O; Schumpelick V; Buell U
    Eur J Nucl Med; 1997 Jun; 24(6):678-82. PubMed ID: 9169578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET evaluation of indeterminate pancreatic masses.
    Ho CL; Dehdashti F; Griffeth LK; Buse PE; Balfe DM; Siegel BA
    J Comput Assist Tomogr; 1996; 20(3):363-9. PubMed ID: 8626891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis?
    Nitzsche EU; Hoegerle S; Mix M; Brink I; Otte A; Moser E; Imdahl A
    Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):237-42. PubMed ID: 11926386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations.
    Sendler A; Avril N; Helmberger H; Stollfuss J; Weber W; Bengel F; Schwaiger M; Roder JD; Siewert JR
    World J Surg; 2000 Sep; 24(9):1121-9. PubMed ID: 11036292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
    Bares R; Klever P; Hauptmann S; Hellwig D; Fass J; Cremerius U; Schumpelick V; Mittermayer C; Büll U
    Radiology; 1994 Jul; 192(1):79-86. PubMed ID: 8208970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results.
    Bares R; Klever P; Hellwig D; Hauptmann S; Fass J; Hambuechen U; Zopp L; Mueller B; Buell U; Schumpelick V
    Nucl Med Commun; 1993 Jul; 14(7):596-601. PubMed ID: 8355920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fluorodeoxyglucose positron emission tomography (FDG-PET) in the differential diagnosis of pancreatic lesions].
    Zimny M; Schumpelick V
    Chirurg; 2001 Sep; 72(9):989-94. PubMed ID: 11594284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem.
    Kato T; Fukatsu H; Ito K; Tadokoro M; Ota T; Ikeda M; Isomura T; Ito S; Nishino M; Ishigaki T
    Eur J Nucl Med; 1995 Jan; 22(1):32-9. PubMed ID: 7698152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
    Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results of positron emission tomography with fluorine-18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma].
    Bares R; Dohmen BM; Cremerius U; Fass J; Teusch M; Büll U
    Radiologe; 1996 May; 36(5):435-40. PubMed ID: 8778929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis.
    van Kouwen MC; Jansen JB; van Goor H; de Castro S; Oyen WJ; Drenth JP
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):399-404. PubMed ID: 15549297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma.
    Reske SN; Grillenberger KG; Glatting G; Port M; Hildebrandt M; Gansauge F; Beger HG
    J Nucl Med; 1997 Sep; 38(9):1344-8. PubMed ID: 9293784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?
    Buck AC; Schirrmeister HH; Guhlmann CA; Diederichs CG; Shen C; Buchmann I; Kotzerke J; Birk D; Mattfeldt T; Reske SN
    J Nucl Med; 2001 May; 42(5):721-5. PubMed ID: 11337566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma.
    Benyounes H; Smith FW; Campbell C; Evans NT; Norton MY; Mikecz P; Heys SD; Bruce D; Eremin O; Sharp PF
    Nucl Med Commun; 1995 Jul; 16(7):575-80. PubMed ID: 7478396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
    Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E
    J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.